



## Novel Drugs for Treating Gynecologic Cancers

Guest Editors:

**Prof. Dr. Tadahiro Shoji**

Department of Obstetrics and  
Gynecology, Iwate Medical  
University, Yahaba, Japan

**Prof. Dr. Hiroaki Itamochi**

Department of Clinical Oncology,  
Iwate Medical University, Yahaba,  
Japan

Deadline for manuscript  
submissions:

**closed (5 January 2025)**

### Message from the Guest Editors

Dear Colleagues,

This Special Issue is titled “Novel Drugs for Treating Gynecologic Cancers”.

Gynecologic cancer treatment has reached a major turning point thanks to the development of molecularly targeted agents and immune-checkpoint inhibitors.

In particular, in ovarian cancer treatment, testing for *BRCA* and HRD status is expected to further improve prognosis by combining molecular targeted agents with different mechanisms of action.

This Special Issue aims to collect original research studies and review articles (either systematic or discursive), clinical trials, and short communications adding to the current knowledge and showing potential future approaches of novel agents for gynecologic cancers.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

*Cancers* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)